Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,096

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Protein drug stability: a formulation challenge

Frokjaer, Sven, Otzen, Daniel E.·2005·Nature Reviews Drug Discovery
DOI 10.1038/nrd1695
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd1695

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 130

  1. Holmer, A. F. Survey: Medicines In Development for HIV/AIDS (Pharmaceutical Research and Manufacturers Association, Washington DC, 2004).
  2. Dobson, C. M. Chemical space and biology. Nature 432, 824–828 (2004). · DOI · Paper page
  3. Pavlou, A. K. & Reichert, J. M. Recombinant protein therapeutics — success rates, market trends and values to 2010. Nature Biotechnol. 22, 1513–1519 (2004). · DOI · Paper page
  4. Krishnamurthy, R. & Manning, M. C. The stability factor: importance in formulation development. Curr. Pharm. Biotech. 3, 361–371 (2002). · DOI
  5. Wang, W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 185, 129–188 (1999). · DOI · Paper page
  6. Hermelin, S., Crommelin, D. J. A., Schellekenes, H. & Jiskoot, W. Structure–immunogenicity relationship of therapeutic proteins. Pharm. Res. 21, 897–903 (2004). · DOI · Paper page
  7. Ahern, T. J. & Manning, M. C. (eds) Stability of Protein Pharmaceuticals — Part A: Chemical and Physical Pathways of Protein Degradation Pharmaceutical Biotechnology Series Vol. 2 (Plenum, New York, 1992).
  8. Cleland, J. L., Powell, M. F. & Shire, S. J. The development of stable protein formulations: a close look at protein aggregation, deamidation and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 10, 307–377 (1993).
  9. Alpar, H. O., Somavarapu, S., Atuah, K. N. & Bramwell, V. W. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug Deliv. Rev. 57, 411–430 (2005). · DOI · Paper page
  10. Hussain, A., Arnold, J. J., Khan, M. A. & Ashan, F. Absorption enhancers in pulmonary protein delivery. J. Control. Release 94, 15–24 (2004). · doi:10.1016/j.jconrel.2003.10.001
  11. Brange, J., Owens, D. R., Kang, S. & Vølund, A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 13, 923–954 (1990). · DOI · Paper page
  12. Kurtzhals, P. et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand–protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 312, 725–731 (1995). · DOI · Paper page
  13. Markussen, J. et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39, 281–288 (1996). · DOI · Paper page
  14. Knudsen, L. B. et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43, 1664–1669 (2000). · DOI · Paper page
  15. Foldvari, M. et al. Palmitoyl derivatives of interferon α: potential for cutaneous delivery. J. Pharm. Sci. 87, 1203–1208 (1998). · DOI
  16. Wang, J., Shen, D. & Shen, W. C. Preparation, purification, and characterization of a reversible lipidized desmopressin with potential anti-diurectic activity. Pharm. Res. 16, 1674–1679 (1999). · DOI
  17. Bhadra, D., Bhadra, S., Jain, P. & Jain, N. K. Pegnology: a review of PEG-ylated systems. Pharmazie 57, 5–29 (2002).
  18. Matthews, S. J. & McCoy, C. Peginteferon α2a: a review of approved and investigational uses. Clin. Ther. 26, 991–1025 (2004). · DOI
  19. Lee, H. -J. & Park, T. G. Preparation and characterization of mono-PEGylated epidermal growth factor: evaluation of in vitro biological activity. Pharm. Res. 19, 845–851 (2002). · DOI
  20. Veronese, F. & Harris, J. M. Introduction and overview of peptide and protein pegylation. Adv. Drug Deliv. Rev. 54, 453–459 (2002). · DOI · Paper page
  21. Dailey, L. A., Wittmar, M. & Kissel, T. The role of branched polyesters and their modifications in the development of modern drug delivery vehicles. J. Control. Release 101, 137–149 (2005). · DOI
  22. Kopecek, J. Smart and genetical engineered biomaterials and drug delivery systems. Eur. J. Pharm. Sci. 20, 1–16 (2003). · DOI · Paper page
  23. Crommelin, D. J. et al. Nanotechnological approaches for the delivery of macromolecules. J. Control. Release 87, 81–88 (2003). · doi:10.1016/s0168-3659(03)00014-2
  24. Peppas, N. A., Bures, P., Leobandung, W. & Ichikawa, H. Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 50, 27–46 (2000). · DOI · Paper page
  25. Packhaeuser, C. B., Schnieders, J., Oster, C. G. & Kissel, T. In situ forming parenteral drug delivery systems: an overview. Eur. J. Pharm. Biopharm. 58, 445–455 (2004). · DOI · Paper page
  26. Metselaar, J. M., Mastrobattista, E. & Storm, G. Liposomes for intravenous drug targeting: design and applications. Mini Rev. Med. Chem. 2, 319–329 (2002). · doi:10.2174/1389557023405873
  27. Muller, R., Radtke, M. & Wissing, S. A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 242, 121–128 (2002). · DOI · Paper page
  28. Bjerregaard, S. et al. Parenteral water/oil emulsions containing hydrophilic compounds with enhanced in vivo retention: formulation, rheological characterization and study of in vivo fate using whole body gammascintography. Int. J. Pharm. 215, 13–27 (2001). · doi:10.1016/s0378-5173(00)00656-6
  29. Pedersen, T. B., Sabra, M. C., Frokjaer, S., Mouritsen, O. G. & Jorgensen, K. Association of acylated cationic decapeptides with dipalmitoylphosphatidylserine-dipalmitoylphosphatidylcholine lipid membranes. Chem. Phys. Lipids 113, 83–95 (2001). · DOI
  30. Jørgensen, K., Davidsen, J. & Mouritsen, O. G. Biophysical mechanisms of phosholipase A2 activation and their use in liposome-based delivery. FEBS Lett. 531, 23–27 (2002). · DOI
  31. Ross, C. et al. Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann. Neurol. 48, 706–712 (2000). · DOI
  32. Sorensen, P. S. et al. Clinical importance of neutralising antibodies against interferon-β in patients with relapsing-remitting multiple sclerosis. Lancet 362, 1184–1191 (2003). · DOI · Paper page
  33. Casadevall, N. et al. Pure red-cell aplasia and antierythropoitin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346, 469–475 (2002). · DOI · Paper page
  34. Casadevall, N. Antibodies against rHuEPO: native and recombinant. Nephro. Dial. Transplant. 17 (Suppl. 5), 42–47 (2002). · DOI
  35. Hermelin, S., Schellekenes, H., Crommelin, D. J. & Jiskoot, W. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm. Res. 20, 1903–1907 (2003). · DOI
  36. Jørgensen, L., Van de Weert, M., Vermehren, C., Bjerregaard, S. & Frokjaer, S. Probing structural changes of proteins incorporated into water-in-oil emulsions. J. Pharm. Sci. 93, 1847–1859 (2004). · DOI
  37. Holm, J. et al. Allergy vaccine engineering: epitope modulation of recombinant Bet v 1 reduces IgE binding but retains protein folding pattern for induction of protective blocking-antibody responses. J. Immunol. 173, 5258–5267 (2004). · DOI
  38. Wang, W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. (in the press). · DOI · Paper page
  39. Fink, A. L. Protein aggregation: folding aggregates, inclusion bodies and amyloid. Folding Des. 3, R9–R29 (1998). · DOI · Paper page
  40. Carpenter, J. F., Kendrick, B. S., Chang, B. S., Manning, M. C. & Randolph, T. W. in Methods in Enzymology (ed. Wetzel, R.) 236–255 (Academic, San Diego, 1999).
  41. Gidalevitz, D., Zhengoing, H. & Rice, S. A. Protein folding at the air–water interface studied with X-ray reflectivity. Proc. Natl Acad. Sci. USA 96, 2608–2611 (1999). · doi:10.1073/pnas.96.6.2608
  42. Nichols, M. R., Moss, M., Reed, D. K., Hoh, J. H. & Rosenberry, T. L. Rapid assembly of amyloid-β peptide at a liquid/liquid interface produces unstable β-sheet fibers. Biochemistry 44, 165–173 (2005). · DOI
  43. Kato, A. & Takagi, T. Formation of intermolecular β-sheet structure during heat denaturation of ovalbumin. J. Agric. Food Chem. 36, 1156–1159 (1988). · DOI
  44. Pedersen, J. S., Christiansen, G. & Otzen, D. E. Modulation of S6 fibrillation by unfolding rates and gatekeeper residues. J. Mol. Biol. 341, 575–588 (2004). · DOI
  45. Fields, G. & Alonso, D. Theory for the aggregation of proteins and copolymers. J. Phys. Chem. B 96, 3674–3981 (1992). · DOI
  46. Chi, E. Y., Krishnan, S., Randolph, T. W. & Carpenter, J. F. Physical stability of proteins in aqueous solution: mechanism and driving forces in non-native protein aggregation. Pharm. Res. 20, 1325–1336 (2003). · DOI · Paper page
  47. Kendrick, B. S., Carpenter, J. F., Cleland, J. L. & Randolph, T. W. A transient expansion of the native state precedes aggregation of recombinant human interferon-γ. Proc. Natl Acad. Sci. USA 95, 14142–14146 (1998). · DOI
  48. Treuheit, M. J., Kosky, A. A. & Brems, D. N. Inverse relationship of protein concentration and aggregation. Pharm. Res. 19, 511–516 (2002). · DOI · Paper page
  49. Krishnan, S. et al. Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition. Biochemistry 41, 6422–6431 (2002). · doi:10.1021/bi012006m
  50. Hevehan, D. & De Bernardez-Clark, E. Oxidative renaturation of lysozyme at high concentrations. Biotechnol. Bioeng. 54, 221–230 (1997). · DOI · Paper page
  51. Gass, J. N., Gunn, K. E., Sriburi, R. & Brewer, J. W. Stressed-out B cells? Plasma-cell differentiation and the unfolded protein response. Trends Immunol. 25, 17–24 (2004). · DOI
  52. London, J., Skrzynia, C. & Goldberg, M. E. Renaturation of Escherichia coli tryptophanase after exposure to 8M urea. Evidence for the existence of nucleation centers. Eur. J. Biochem. 47, 409–415 (1974). · DOI · Paper page
  53. Chapman, M. R. et al. Role of Eschericia coli curli operons in directing amyloid fiber formation. Science 295, 851–855 (2002). · DOI · Paper page
  54. Huff, M. E., Balch, W. E. & Kelly, J. W. Pathological and functional amyloid formation orchestrated by the secretory pathway. Curr. Op. Struct. Biol. 13, 674–682 (2003). · DOI
  55. Sunde, M. et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol. 273, 729–739 (1997). · DOI · Paper page
  56. Dobson, C. M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24, 329–332 (1999). · DOI · Paper page
  57. Harper, J. D. & Lansbury, P. T. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385–407 (1997). · DOI · Paper page
  58. Cao, Z. & Ferrone, F. A. A 50th order reaction predicted and observed for sickle hemoglobin nucleation. J. Mol. Biol. 256, 219–222 (1996). · DOI
  59. Patro, S. Y. & Przybycien, T. M. Simulations of kinetically irreversible protein aggregate structure. Biophys. J. 66, 1274–1289 (1994). · DOI
  60. Istrail, S., Schwartz, R. & King, J. Lattice simulations of aggregation funnels for protein folding. J. Comput. Biol. 6, 143–162 (1999). · doi:10.1089/cmb.1999.6.143
  61. Ferrone, F. Analysis of protein aggregation kinetics. Meth. Enzymol. 309, 256–274 (1999). · DOI · Paper page
  62. Clark, P. L. Protein folding in the cell: reshaping the folding funnel. Trends Biochem. Sci. 29, 527–534 (2004). · DOI · Paper page
  63. Chiti, F. et al. Kinetic partitioning of protein folding and aggregation. Nature Struct. Biol. 9, 137–143 (2002). · DOI · Paper page
  64. Kunjithapatham, R. et al. Role for the α-helix in aberrant protein aggregation. Biochemistry 44, 149–156 (2005). · DOI
  65. Fernandez-Escamilla, A. M., Rousseau, F., Schymkowitz, J. & Serrano, L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and protein. Nature Biotechnol. 22, 1302–1306 (2004). · DOI · Paper page
  66. DuBay, K. F. et al. Predicting absolute aggregation rates of amyloidogenic polypeptide chains. J. Mol. Biol. 341, 1317–1326 (2004). · DOI · Paper page
  67. Fraser, P. E. et al. Conformation and fibrillogenesis of Alzheimer Aβ peptides with selected substitution of charged residues. J. Mol. Biol. 244, 64–73 (1994). · DOI
  68. Frokjaer, S. et al. Probing the mechanism of insulin fibril formation with insulin mutants. Biochemistry 40, 8397–8409 (2001). · DOI · Paper page
  69. Otzen, D. E., Kristensen, P. & Oliveberg, M. Designed protein tetramer zipped together with an Alzheimer sequence: a structural clue to amyloid assembly. Proc. Natl Acad. Sci. USA 97, 9907–9912 (2000). · DOI · Paper page
  70. Otzen, D. E. & Oliveberg, M. Salt-induced detour through compact regions of the protein folding landscape. Proc. Natl Acad. Sci. USA 96, 11746–11751 (1999). · DOI
  71. Ferrone, F. Analysis of protein aggregation kinetics. Meth. Enzymol. 309, 256–274 (1999). · DOI · Paper page
  72. Hall, D. & Edskes, H. Silent prions lying in wait: a two-hit model of prion/amyloid formation and infection. J. Mol. Biol. 336, 775–786 (2004). · DOI
  73. Masel, J. & Jansen, V. A. Designing drugs to stop the formation of prion aggregates and other amyloids. Biophys. Chem. 88, 47–59 (2000). · DOI
  74. Chen, S., Ferrone, F. & Wetzel, R. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc. Natl Acad. Sci. USA 99, 11884–11889 (2002). · DOI · Paper page
  75. Krebs, M. R., Morozova-Roche, L. A., Daniel, K., Robinson, C. V. & Dobson, C. M. Observation of sequence specificity in the seeding of protein amyloid fibrils. Protein Sci. 13, 1933–1938 (2004). · DOI · Paper page
  76. Wadai, H. et al. Stereospecific amyloid-like fibril formation by a peptide fragment of β2-microglobulin. Biochemistry 44, 157–164 (2005). · doi:10.1021/bi0485880
  77. O'Nuallain, B., Williams, A. D., Westermark, P. & Wetzel, R. Seeding specificity in amyloid growth induced by heterologous fibrils. J. Biol. Chem. 279, 17490–17499 (2004). · DOI · Paper page
  78. Petkova, A. T. et al. Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science 307, 262–265 (2005). · DOI · Paper page
  79. Kardos, J., Yamamoto, K., Hasegawa, K., Naiki, H. & Goto, Y. Direct measurement of the thermodynamic parameters of amyloid formation by isothermal titration calorimetry. J. Biol. Chem. 279, 55308–55314 (2004). · DOI
  80. Perutz, M. F., Finch, J. T., Berriman, J. & Lesk, A. Amyloid fibers are water-filled nanotubes. Proc. Natl Acad. Sci. USA 99, 5591–5595 (2002). · DOI · Paper page
  81. Onoue, S. et al. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm. Res. 21, 1274–1283 (2004). · DOI
  82. Wurth, C., Guimard, N. K. & Hecht, M. H. Mutations that reduce aggregation of the Alzheimer's Aβ42 peptide: an unbiased search for the sequence determinants of Aβ amyloidogenesis. J. Mol. Biol. 319, 1279–1290 (2002). · DOI · Paper page
  83. Manning, M. & Colón, W. Structural basis of protein kinetic stability: resistance to sodium dodecyl sulfate suggests a central role for rigidity and a bias toward β-sheet structure. Biochemistry 43, 11248–11254 (2004). · DOI · Paper page
  84. Klibanov, A. M. Why are enzymes less active in organic solvents than in water? Trends Biotechnol. 15, 97–101 (1997). · DOI · Paper page
  85. Partridge, J., Moore, B. D. & Halling, P. J. α-chymotrypsin stability in aqueous-acetonitrile mixtures: is the native enzyme thermodynamically or kinetically stable under low water conditions? J. Mol. Catal., B Enzym. 6, 11–20 (1999). · doi:10.1016/s1381-1177(98)00105-2
  86. Machius, M., Declerck, N., Huber, R. & Wiegand, G. Kinetic stabilization of Bacillus licheniformis α-amylase through introduction of hydrophobic residues at the surface. J. Biol. Chem. 278, 11546–11553 (2003). · DOI
  87. Murphy, C. M. Peptide aggregation in neurodegenerative disease. Annu. Rev. Biomed. Eng. 4, 155–174 (2002). · DOI · Paper page
  88. Conway, K. A., Rochet, J. -C., Bieganski, R. M. & Lansbury, P. T. Kinetic stabilization of the α-synuclein protofibril by a dopamine–α-synuclein adduct. Science 294, 1346–1349 (2001). · DOI · Paper page
  89. Taniguchi, S. et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280, 7614–7623 (2005). · DOI · Paper page
  90. Rzepecki, P. et al. Prevention of Alzheimer's disease-associated Aβ aggregation by rationally designed nonpeptidic β-sheet ligands. J. Biol. Chem. 279, 47497–47505 (2004). · DOI
  91. Gestwicki, J. E., Crabtree, G. R. & Graef, I. A. Harnessing chaperones to generate small-molecule inhibitors of amyloid β aggregation. Science 306, 865–869 (2004). · DOI · Paper page
  92. Shire, S. J., Shahrokh, Z. & Liu, J. H. Challenges in the development of high protein concentration formulations. J. Pharm. Sci. 93, 1390–1402 (2004). · DOI · Paper page
  93. Timasheff, S. Protein hydration, thermodynamic binding, and preferential hydration. Biochemistry 41, 13473–13482 (2002). · DOI · Paper page
  94. Baldwin, R. L. How Hofmeister ion interactions affect protein stability. Biophys. J. 71, 2056–2063 (1996). · DOI · Paper page
  95. De Bernardez-Clark, E., Schwarz, E. & Rudolph, R. Inhibition of aggregation side reactions during in vitro protein folding. Meth. Enzymol. 309, 217–236 (1999). · DOI · Paper page
  96. Golovanov, A. P., Hautbergue, G. M., Wilson, S. A. & Lian, L. -Y. A simple method for improving protein solubility and long-term stability. J. Am. Chem. Soc. 126, 8933–8939 (2004). · DOI · Paper page
  97. Webb, S. D., Cleland, J. L., Carpenter, J. F. & Randolph, T. W. A new mechanism for decreasing aggregation of recombinant human interferon-γ by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20. J. Pharm. Sci. 91, 543–558 (2002). · DOI
  98. Kerwin, B. A., Heller, M. C., Levin, S. H. & Randolph, T. W. Effects of Tween 80 and sucrose on acute short-term stability and long-term storage at −20° C of a recombinant hemoglobin. J. Pharm. Sci. 87, 1062–1068 (1998). · doi:10.1021/js980140v
  99. Arakawa, T. & Kita, Y. Protection of bovine serum albumin from aggregation by Tween 80. J. Pharm. Sci. 89, 646–651 (2000). · doi:10.1002/(sici)1520-6017(200005)89:5<646::aid-jps10>3.0.co;2-j
  100. Rozema, D. & Gellman, S. H. Artificial chaperone-assisted refolding of carbonic anhydrase B. J. Biol. Chem. 271, 3478–3487 (1996). · DOI · Paper page
  101. Tsai, A. M., van Zanten, J. H. & Betenbaugh, M. J. II: Electrostatic effect in the aggregation of heat-denatured RNase A and implications for protein additive design. Biotechnol. Bioeng. 59, 281–285 (1998). · doi:10.1002/(sici)1097-0290(19980805)59:3<281::aid-bit3>3.0.co;2-7
  102. Zhao, H., Tuominen, E. K. J. & Kinnunen, P. K. J. Formation of amyloid fibers triggered by phosphatidylserine-containing membranes. Biochemistry 43, 10302–10307 (2004). · DOI · Paper page
  103. Knight, J. D. & Miranker, A. D. Phospholipid catalysis of diabetic amyloid assembly. J. Mol. Biol. 341, 1175–1187 (2004). · DOI · Paper page
  104. Necula, M., Chirita, C. N. & Kuret, J. Rapid anionic micelle-mediated α-synuclein fibrillization in vitro. J. Biol. Chem. 278, 46674–46680 (2003). · DOI
  105. Chirita, C. N. & Kuret, J. Evidence for an intermediate in tau filament formation. Biochemistry 43, 1704–1714 (2004). · DOI
  106. Frömming, K. -H. & Szejtli, J. Cyclodextrins in Pharmacy (Kluwer Academic, Dordrecht, 1994). · DOI · Paper page
  107. Larsen, K. L. Large cyclodextrins. Biol. J. Armenia 53, 9–26 (2001).
  108. Banga, A. K. & Mitra, R. Minimization of shaking-induced formation of insoluble aggregates of insulin by cyclodextrins. J. Drug Target. 1, 341–345 (1993). · doi:10.3109/10611869308996093
  109. Dotsikas, Y. & Loukas, Y. L. Kinetic degradation study of insulin complexed with methyl-β cyclodextrin. Confirmation of complexation with electrospray mass spectrometry and 1H-NMR. J. Pharm. Biomed. Anal. 29, 487–494 (2002). · doi:10.1016/s0731-7085(02)00076-6
  110. Tokihiro, K., Irie, T., Uekama, K. & Pitha, J. Potential use of maltosyl-β-cyclodextrin for inhibition of insulin self-association in aqueous solution. Pharm. Sci. 1, 49–53 (1995).
  111. Otzen, D. E., Knudsen, B. R., Aachmann, F. L., Larsen, K. L. & Wimmer, R. Structural basis for cyclodextrins' suppression of human growth hormone aggregation. Protein Sci. 11, 1779–1787 (2002). · DOI
  112. Hagenlocher, M. & Pearlman, R. Use of a substituted cyclodextrin for stabilization of solutions of recombinant human growth hormone. Pharm. Res. 6, S30 (1989).
  113. Sharma, L. & Sharma, A. Influence of cyclodextrin ring substituents on folding-related aggregation of bovine carbonic anhydrase. Eur. J. Biochem. 268, 2456–2463 (2001). · DOI
  114. Sigurjonsdottir, J. F., Loftsson, T. & Masson, M. Influence of cyclodextrins on the stability of the peptide salmon calcitonin in aqueous solution. Int. J. Pharm. 186, 205–213 (1999). · doi:10.1016/s0378-5173(99)00183-0
  115. Aachmann, F. L., Otzen, D. E., Larsen, K. L. & Wimmer, R. Structural background of cyclodextrin–protein interactions. Protein Eng. 16, 1–8 (2003). · doi:10.1093/protein/gzg137
  116. Cooper, A. Effect of cyclodextrins on the thermal stability of globular proteins. J. Am. Chem. Soc. 114, 9208–9209 (1992). · doi:10.1021/ja00049a074
  117. Otzen, D. E. & Oliveberg, M. A simple way to measure protein refolding rates in water. J. Mol. Biol. 313, 479–483 (2001). · DOI
  118. Karuppiah, N. & Sharma, A. Cyclodextrins as protein folding aids. Biochem. Biophys. Res. Commun. 211, 60–66 (1995). · doi:10.1006/bbrc.1995.1778
  119. Easton, C. J. & Lincoln, S. F. Modified Cyclodextrins: Scaffolds and Templates for Supramolecular Chemistry (Imperial College Press, London, 1999). · doi:10.1142/p124
  120. Szejtli, J & Osa, T (eds). Comprehensive Supramolecular Chemistry (Elsevier Science, Oxford, 1996).
  121. Franks, F. Protein destabilization at low temperatures. Adv. Protein Chem. 46, 105–139 (1995). · doi:10.1016/s0065-3233(08)60333-2
  122. Wang, W. Lyophilization and development of slid protein pharmaceuticals. Int. J. Pharm. 203, 1–60 (2000). · DOI · Paper page
  123. Franks, F. Freeze-drying of bioproducts: putting principles into practice. Eur. J. Pharm. Biopharm. 45, 221–229 (1998). · DOI · Paper page
  124. Franks, F. Long-term stabilization of biologicals. Biotechnology (NY) 12, 253–256 (1994). · DOI
  125. Levine, H. & Slade, L. Water as a plasticizer: physico-chemical aspects of low-moisture polymeric systems. Water Sci. Rev. 3, 79–185 (1988). · DOI · Paper page
  126. Costantino, H. R., Langer, R. & Klibanov, A. M. Moisture-induced aggregation of lyophilized insulin. Pharm. Res. 11, 21–29 (1994). · doi:10.1023/a:1018981208076
  127. Yoshioka, S., Aso, Y., Izutsu, K. & Terao, T. Aggregates formed during storage of β-galactosidase in solution and in the freeze-dried state. Pharm. Res. 10, 687–691 (1993). · doi:10.1023/a:1018951530927
  128. Klibanov, A. M. & Schefiliti, J. A. On the relationship between conformation and stability in solid pharmaceutical protein formulations. Bioctechnol. Lett. 26, 1103–1106 (2004). · doi:10.1023/b:bile.0000035520.47933.a6
  129. Brange, J., Andersen, L., Laursen, E. D., Meyn, G. & Rasmussen, E. Toward understanding insulin fibrillation. J. Pharm. Sci. 86, 517–525 (1997). · DOI · Paper page
  130. Malencik, D. A. & Anderson, S. R. Dityrosine as a product of oxidative stress and fluorescent probe. Amino Acids 25, 233–247 (2003). · DOI · Paper page

Cited by

See all 1,096

Metadata

Authors
Frokjaer, S., & Otzen, D. E.
Venue
Nature Reviews Drug Discovery
Publisher
Springer Science and Business Media LLC
Published
2005-04
Volume
4
Issue
4
Pages
298-306
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
DOI
10.1038/nrd1695
OpenAlex
W1970898345
Cited by
1,096
References
7
FWCI
1.53
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Protein drug stability: a formulation challenge. https://app.cochat.ai/papers/10.1038/nrd1695
The paper
Frokjaer, S., & Otzen, D. E. (2005). Protein drug stability: a formulation challenge. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd1695

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.